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Formatting errors in Table [3](#jvim15786-tbl-0001){ref-type="table"}. Most common adverse events (AEs) and associated Veterinary Cooperative Oncology Group (VCOG) grades encountered in study population.

###### 

Most common adverse events (AEs) and associated Veterinary Cooperative Oncology Group (VCOG) grades encountered in study population. Multiple events are reported for each dog if encountered during the study

  Grade                     1                                             2                                              3                                                                                            4                                             5
  ------------------------- --------------------------------------------- ---------------------------------------------- -------------------------------------------------------------------------------------------- --------------------------------------------- ---
  **Gastrointestinal**                                                                                                                                                                                                                                              
  Hyporexia                 10                                            8                                              5[^b^](#jvim15786-note-0002){ref-type="fn"}                                                                                                
  Diarrhea                  14                                            11[^c^](#jvim15786-note-0003){ref-type="fn"}   3[^c^](#jvim15786-note-0003){ref-type="fn"}                                                                                                
  Hematochezia/ melena      3                                             1                                                                                                                                                                                         
  Vomiting                  10                                            5                                              1[^c^](#jvim15786-note-0003){ref-type="fn"}                                                                                                
  Weight loss               6                                             4                                              7[^b^](#jvim15786-note-0002){ref-type="fn"} ^,^ [^c^](#jvim15786-note-0003){ref-type="fn"}                                                 
  **Hematologic**                                                                                                                                                                                                                                                   
  Anemia                    11                                            1[^c^](#jvim15786-note-0003){ref-type="fn"}    1[^a^](#jvim15786-note-0001){ref-type="fn"}                                                                                                
  Neutropenia               4                                             1                                              1                                                                                            1[^c^](#jvim15786-note-0003){ref-type="fn"}   
  Thrombocytopenia          6                                             3[^c^](#jvim15786-note-0003){ref-type="fn"}    2[^c^](#jvim15786-note-0003){ref-type="fn"}                                                  1[^a^](#jvim15786-note-0001){ref-type="fn"}   
  **Cutaneous/Pulmonary**                                                                                                                                                                                                                                           
  Dermatopathy              9[^c^](#jvim15786-note-0003){ref-type="fn"}   5                                              1[^b^](#jvim15786-note-0002){ref-type="fn"}                                                                                                
  Pulmonary fibrosis        1                                                                                                                                                                                                                                       
  Pneumonia                 1                                                                                                                                                                                                                                       

Evan\'s syndrome suspected to be unrelated to rabacfosadine/L‐asparaginase.

Adverse events resulting in withdrawal from study in select cases.

Adverse events resulting in dose reduction or dose delay in select cases.

There are 3 groupings of events. The header of "Gastrointestinal" is only for "Hyporexia," "Diarrhea,"

"Hemtaochezia/melena," "Vomiting," and "Weight loss." There should be header of "Hematologic" for "Anemia," "Neutopenia," and "Thrombocyopenia" and a header of "Cutaneous/Pulmonary" for "Demotapathy," "Pulmonary fibrosis," and "Pneumonia."
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